نتائج البحث - Joan Cox Gill

تنقيح النتائج
  1. 1
    Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project

    Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project حسب Marilyn Johnson, J. Michael Soucie, Joan Cox Gill

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    High‐dose DDAVP intranasal spray (Stimate<sup>®</sup>) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A

    High‐dose DDAVP intranasal spray (Stimate<sup>®</sup>) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand dise... حسب Cindy Leissinger, David L. Becton, Charles J. Cornell, Joan Cox Gill

    منشور في 2001
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets

    Identification of FcγRIIa as the ITAM-bearing receptor mediating αIIbβ3 outside-in integrin signaling in human platelets حسب Brian Boylan, Cunji Gao, Vipul Rathore, Joan Cox Gill, Debra K. Newman, Peter J. Newman

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage

    Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage حسب Paula M. Jacobi, Joan Cox Gill, Veronica H. Flood, David Jakab, Kenneth D. Friedman, Sandra L. Haberichter

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function

    Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function حسب Veronica H. Flood, Kenneth D. Friedman, Joan Cox Gill, Patricia A. Morateck, J.S. WREN, John P. Scott, Robert R. Montgomery

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain

    Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcγRIIa and the integrin β3 cytoplasmic domain حسب Cunji Gao, Brian Boylan, Dan Bougie, Joan Cox Gill, Jessica Birenbaum, Debra K. Newman, Richard H. Aster, Peter J. Newman

    منشور في 2009
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

    Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network حسب Thomas C. Abshire, Joan Cox-Gill, Christine L. Kempton, Frank W.G. Leebeek, Manuel Carção, Peter A. Kouides, Sharyne Donfield, Erik Berntorp

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD

    Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD حسب Veronica H. Flood, Joan Cox Gill, Patricia A. Morateck, Pamela A. Christopherson, Kenneth D. Friedman, Sandra L. Haberichter, Raymond G. Hoffmann, Robert R. Montgomery

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease

    Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease حسب Veronica H. Flood, Joan Cox Gill, Kenneth D. Friedman, Pamela A. Christopherson, Paula M. Jacobi, Raymond G. Hoffmann, Robert R. Montgomery, Sandra L. Haberichter

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival

    Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival حسب Sandra L. Haberichter, Michael Balistreri, Pamela A. Christopherson, Patricia A. Morateck, Stefana Gavazova, Daniel B. Bellissimo, Marilyn J. Manco‐Johnson, Joan Cox Gill, Robert R. Montgomery

    منشور في 2006
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Type 2M von Willebrand Disease: F606I and I662F Mutations in the Glycoprotein Ib Binding Domain Selectively Impair Ristocetin- but not Botrocetin-Mediated Binding of von Willebrand Factor to Platelets

    Type 2M von Willebrand Disease: F606I and I662F Mutations in the Glycoprotein Ib Binding Domain Selectively Impair Ristocetin- but not Botrocetin-Mediated Binding of von Willebrand... حسب Cheryl A. Hillery, David J. Mancuso, J. Evan Sadler, Jay W. Ponder, Mary A. Jozwiak, Pamela A. Christopherson, Joan Cox Gill, James G. Scott, Robert R. Montgomery

    منشور في 1998
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Thrombolysis in Pediatric Stroke Study

    Thrombolysis in Pediatric Stroke Study حسب Michael Rivkin, Gabrielle deVeber, Rebecca Ichord, Adam Kirton, Anthony K.C. Chan, Collin A. Hovinga, Joan Cox Gill, Anikó Szabó, Michael D. Hill, Kelley Scholz, Catherine Amlie‐Lefond

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease

    Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease حسب Joan Cox Gill, Giancarlo Castaman, Jerzy Windyga, Peter A. Kouides, Margaret V. Ragni, Frank W.G. Leebeek, Ortrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava G. Pavlova, Isabella Presch, Bruce M. Ewenstein

    منشور في 2015
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Crucial role for the VWF A1 domain in binding to type IV collagen

    Crucial role for the VWF A1 domain in binding to type IV collagen حسب Veronica H. Flood, Abraham Schlauderaff, Sandra L. Haberichter, Tricia L. Slobodianuk, Paula M. Jacobi, Daniel B. Bellissimo, Pamela A. Christopherson, Kenneth D. Friedman, Joan Cox Gill, Raymond G. Hoffmann, Robert R. Montgomery

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)

    Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) حسب Thomas C. Abshire, Augusto B. Federici, M. T. Alvárez, Joel Bowen, Manuel Carção, Joan Cox Gill, Nigel S. Key, Peter A. Kouides, Karin Kurnik, Alice Lail, Frank W.G. Leebeek, Michael Makris, P.M. Mannucci, Rochelle Winikoff, E. Berntorp

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population

    VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population حسب Daniel B. Bellissimo, Pamela A. Christopherson, Veronica H. Flood, Joan Cox Gill, Kenneth D. Friedman, Sandra L. Haberichter, Amy D. Shapiro, Thomas C. Abshire, Cindy Leissinger, W. Keith Hoots, Jeanne M. Lusher, Margaret V. Ragni, Robert R. Montgomery

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres

    Surveillance of female patients with inherited bleeding disorders in United States Haemophilia Treatment Centres حسب Vanessa R. Byams, Peter A. Kouides, R. KULKARNI, Judith Baker, Deborah Brown, Joan Cox Gill, Althea M. Grant, Allison James, Barbara A. Konkle, Jennifer Maahs, M Dumas, S. McALISTER, Danielle Nance, Diane J. Nugent, Claire S. Philipp, J. Michael Soucie, Ellen Stang

    منشور في 2011
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System

    Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System حسب Roshni Kulkarni, Rodney Presley, Jeanne M. Lusher, Amy D. Shapiro, Joan Cox Gill, M. Manco‐Johnson, Marion A. Koerper, Thomas C. Abshire, Donna DiMichele, W. Keith Hoots, Prasad Mathew, Diane J. Nugent, S. Geraghty, Bruce L. Evatt, J. Michael Soucie

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial

    Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial حسب Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar, Edward H. Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, T. T. Yee, Robert Klamroth, Wing-Yen Wong, Miranda Chapman, Werner Engl, Peter L. Turecek, Tobias M. Suiter, Bruce M. Ewenstein

    منشور في 2013
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Comparative pharmacokinetics of <scp>rVIII</scp>‐SingleChain and octocog alfa (Advate<sup>®</sup>) in patients with severe haemophilia A

    Comparative pharmacokinetics of <scp>rVIII</scp>‐SingleChain and octocog alfa (Advate<sup>®</sup>) in patients with severe haemophilia A حسب Robert Klamroth, Mindy L. Simpson, M. von Depka‐Prondzinski, Joan Cox Gill, Massimo Morfini, Jerry S. Powell, Elena Santagostino, Joanna A. Davis, Angela Huth‐Kühne, Cindy Leissinger, Peter Neumeister, Debra M. Bensen-Kennedy, Annette Feussner, Tharin Limsakun, Meijian Zhou, Alex Veldman, Katie St. Ledger, Nicole Blackman, Ingrid Pabinger

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: